Prohibiting a carrier from reimbursing a health care practitioner in an amount that is less than the cost to the health care practitioner for the cost of an oncology drug used in treating a patient in the office of the health care practitioner; and providing an exception to the prohibition if a carrier provides an alternative mechanism or program for the health care practitioner to use to obtain the oncology drug.